Uncategorized Archives - Page 66 of 86 - PsychedelicNewsWire (PNW)

ThursdayJul 09, 2020 10:00 am

US Doctor Requests Temporary FDA Approval of Psychedelics to Fight Covid-19 Related Trauma

As COVID-19 continues to wreak havoc globally, it seems medics may have to turn to psychedelics to help deal with the anxiety and depression triggered by the pandemic. Psychedelic-based medications currently feature three major substances; MDMA, LSD, and Psilocybin, commonly referred to as Magic Mushrooms. Psychedelics are yet to be legalized worldwide because of the stigma attached to the 'drug.' The good news is that clinical studies are providing accurate data about these substances, and are revealing how effective they are when administered under medical supervision. U.S. psychiatrist Dr. Morgan Campbell recently brought the matter to light while addressing the…

WednesdayJul 08, 2020 2:00 pm

COVID-19 Likely to Give Psychedelics a Boost

Pharmacists are proposing psychedelics therapy as a measure to deal with the mental health issues caused by the COVID-19 pandemic. Previous experience with 2003’s SARS (severe acute respiratory syndrome) revealed the overwhelming trauma that such a pandemic can cause. It’s projected that the COVID-19 pandemic will have similar or worse cases of post-traumatic stress disorder. Considering many have lost loved ones, jobs, homes, disruption of learning, separation, and so much more, it is likely to take a huge toll on people. Cases of suicides, addiction, stress, and depression may be on the rise. Dr. Morgan Campbell, a psychiatrist from Wisconsin,…

WednesdayJul 08, 2020 10:56 am

Pure Extract Technologies Inc. Set to Become Dominant Extraction Company in Growing Mushroom Space

Functional mushrooms seeing rise in popularity due to health benefits, alternative medicine options Predictions show global medicinal mushroom market growing annually by $13.88 billion Pure Extracts is ideally positioned to enter the space as experienced producer Used for centuries for their impressive medicinal properties and health benefits, functional mushrooms are enjoying a rise in popularity, due at least in part to increased research and study of the natural fungi as well as trends toward alternative natural health options. Pure Extract Technologies, a private, plant-based extraction company with a new vertical in functional mushrooms, is focused on becoming the dominant extraction…

WednesdayJul 08, 2020 10:00 am

How Psychedelics Could End the Opioid Pandemic

Due to the ongoing global spread of the novel coronavirus, some ailments have been ignored as potential threats to global health. One of these is the widespread opioid epidemic in the U.S. Purdue Pharma is a pharmaceutical company, currently run by the Sackler family, which many say has contributed a lot to the opioid epidemic running across the U.S. Purdue Pharma is believed to have played a big role in the making of the killer Oxycotin. Opioids were initially given a suspicious clean bill of health by numerous doctors and scientists who claimed that they were not addictive. This approval…

TuesdayJul 07, 2020 4:00 pm

Military Puts $27M into Developing Psychedelic-Based Medicines

One of the biggest health challenges affecting the modern world is depression and substance addiction. The treatments for these conditions vary, but almost always end up in prescription pills. The U.S. military seems determined to change this, according to reports reaching media houses. Over the years, people have visited therapists and psychiatrists seeking help due to depression, anxiety, stress, and PTSD (post-traumatic stress disorder), and doctors prescribe drugs to help them with these situations. Of recent, governmental departments, one being DARPA (Defense Advanced Research Projects Agency), have started investing in researching for a new class of drugs that will enhance…

TuesdayJul 07, 2020 3:04 pm

Cybin Corp. is “One to Watch”

Cybin is a leading Canada-based mushroom life sciences company focused on psychedelic medicines and nutraceutical products The company has two operating divisions – Serenity Life Sciences (psychedelic pharmaceutical products) and Natures Journey Inc. (medicinal nutraceutical products) Members of Cybin’s experienced management team have collectively run multiple clinical trials and helped facilitate over $1 billion in pharmaceutical sales The company recently announced a strategic partnership with the Toronto Centre for Psychedelic Science Cybin is currently marketing a range of fungi-based supplements under its Journey brand aimed at breaking into the global non-psychedelic legal supplement market, which is valued at $25 billion…

TuesdayJul 07, 2020 10:00 am

Clinical Trial on Treating Cluster Headaches Using LSD Underway

A Phase 2 clinical trial on how LSD can be used to treat cluster headaches is underway in Switzerland. The trial is being conducted at Liechti Lab at University Hospital Basel. Patients willing to participate in this study were recruited in January this year and the trial is now underway. Cluster headaches are also referred to as “suicide headaches” since the pain they cause is so severe that many patients with this condition develop suicidal tendencies during an episode. Cluster headaches have also been variously described as the most painful condition that anyone can ever suffer from. The pain caused…

MondayJul 06, 2020 3:00 pm

Psilocybin Ballot Initiative Likely in Colorado After Voters Show Strong Support

RBI Strategies & Research conducted a poll in Colorado between March 17 and 19 this year, and the findings of that poll are out. The survey results have given activists the impetus that they need to consider putting a psilocybin ballot measure on the 2022 ballot. This positive news comes approximately one year after the city of Denver made history as the first U.S. city to decriminalize the possession of “magic mushrooms.” This milestone was reached after the tireless work done by “Decriminalize Denver” paid off. Now the recent survey conducted by RBI has provided more good news for the…

MondayJul 06, 2020 10:00 am

Phase 1 Clinical Trial Planned to Evaluate DMT

Mind Medicine (NEO: MMED) (OTCQB: MMEDF) (“MindMed”) recently announced that it was providing funding for a Phase 1 clinical trial aimed at evaluating the main psychotropic active ingredient dimethyltryptamine (“DMT”) found in ayahuasca. This clinical trial is slated to begin in the fourth quarter of this year. DMT occurs naturally and is the primary reason why the indigenous shamanic practitioners in the Amazon use ayahuasca in their ceremonies. However, DMT quickly triggers its psychoactive effects and these effects also wear off a lot sooner than those of other psychedelic ingredients like LSD and psilocybin. When DMT is administered as an…

ThursdayJul 02, 2020 3:45 pm

Activists Say Oregon Psilocybin Ballot Measure Obtained Enough Signatures for November Poll

Activists behind an initiative to legalize magic (psilocybin) mushrooms in Oregon for medicinal purposes have announced that they gathered a lot more than the required number of voter signatures in order for the measure to qualify for the polls in November. While Oregon’s Secretary of State hasn’t verified all those signatures, the advocates behind the “Yes on IP34” say that according to their independent audit, the campaign exceeded the minimum number of required signatures before the deadline on July 2. Their confidence may not be misplaced, given that the office of the Secretary of State had confirmed that the first…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized